The abstract is read at the publisher; the summary is JClub's.
In 301 treatment-naive SSc-PAH patients from EUSTAR (2000–2021), sustained initial monotherapy or combination therapy was linked to lower mortality (HR 0.50 and 0.40) and progression (HR 0.37).
- Why it matters: Real-world initial treatment patterns in systemic sclerosis-associated pulmonary arterial hypertension are not well characterized across hemodynamic thresholds and risk strata, limiting interpretation of observational outcomes.
- What they did: The study analyzed therapy started within four months of right heart catheterization in patients meeting the 2022 hemodynamic definition, using adjusted as-treated primary analyses and supportive intention-to-treat analyses for all-cause mortality and 36-month PAH progression.
- The result: As-treated analyses showed lower mortality with sustained monotherapy and combination therapy and lower PAH progression risk with sustained initial therapy, while adjusted intention-to-treat analyses found no association; milder hemodynamic subgroup estimates were directionally consistent but imprecise.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.